Health economics and policy evaluation research

We are a multidisciplinary team that brings together health economists, epidemiologists and pharmacists. We work across a number of therapeutic streams within MIPS, and collaborate with government agencies, industry, and consumer representatives to optimise healthcare in Australia. We specialise in economic evaluation alongside clinical trials and observational studies, epidemiological and health economic modelling, and health technology assessment (HTA).

To date, our work has benefited healthcare worldwide through enhancing evidence-based practice, improving clinical guidelines, and driving policy change. Health economic decision models and new health metrics designed through our research program have provided evidence on the benefits and costs of health interventions where little or no evidence previously existed. Substantiation of cost-effectiveness has enabled key decision makers (both national governments and private payers) to enact effective healthcare policies, improving healthcare and promoting equity.


PhD students

  • Tamrat Abebe
  • Dina Abushanab
  • Yeji Baek
  • Padam Dahal
  • Bo Wen
  • Maria (Majo) Arvez
  • Sheridan Rodda
  • Adam Livori

Postdoctoral guest researcher

  • Dr Kristopher Jarlov Jensen
  • Cardiovascular Disease and Diabetes
  • Epilepsy
  • Genomics
  • Oncology
  • Neurodegenerative Diseases
  • Vaccines
  • Musculoskeletal disorders
  • Economic evaluation alongside clinical trials, cohort and case control studies
  • Decision health economic modelling
  • Budget impact analysis and return on investment
  • Distributional cost-effectiveness analysis (DCEA)
  • Epidemiological modelling
  • Economic evaluation of clinical pharmacy services
  • Health technology assessment (HTA), systematic reviews and meta-analyses
  • Quantifying disease burden through productivity measurement
  • Data linkage and analysis of administrative data such as the Pharmaceutical Benefit Scheme (PBS) and Medicare Benefits Schedule (MBS)